Lung transplantation is currently considered as an ultimate live-saving treatment for selected patients suffering from end-stage pulmonary disease. Long-term survival, however, is hampered by chronic rejection, or chronic lung allograft dysfunction (CLAD). Recently, various phenotypes within CLAD have been identified, challenging the established clinical definition of Bronchiolitis Obliterans Syndrome (BOS). Some patients with presumed BOS for instance, demonstrate an important improvement in FEV 1 after treatment with azithromycin. These patients are characterized by the presence of excess (≥15%) BAL neutrophils, in absence of concurrent infection. This phenotype of CLAD has been redefined as neutrophilic reversible allograft dysfunction (NRAD) and these patients generally have a very good prognosis after diagnosis.
Introduction
Lung transplantation (LTx) has become an established treatment option for patients with end-stage pulmonary diseases like COPD, cystic fibrosis, pulmonary fibrosis, pulmonary arterial hypertension, ... Survival after LTx, however, remains rather poor as only 55% of patients survive more than 5 years according to the registry of the International Society for Heart and lung Transplantation (ISHLT) database (1) . Early post-operative complications include primary graft dysfunction (2) , infections, suture stenosis (3), acute rejection (4) and lymphocytic bronchiolitis (LB) (5) . Long-term survival is limited by infections and the development of chronic rejection or chronic lung allograft dysfunction (CLAD), which may clinically manifest as Bronchiolitis Obliterans Syndrome (BOS), an obstructive decline in FEV 1 of at least 20% compared to the best post-operative value in the absence of other identifiable factors like acute rejection, suture stenosis, infection, … It was the general believe that BOS was characterized by: A/ neutrophilic airway inflammation, B/ largely irreversible and persistent obstructive pulmonary function decline, and C/ a fibroproliferative narrowing of the bronchioles (6) .
As diagnostic yield of transbronchial biopsies is very low (7), a decline in FEV 1 of at least 20% is regarded as the hallmark of chronic rejection in the absence of other identifiable causes. There is now accumulating evidence that not every persistent decline in FEV 1 is compatible with this definition and as a consequence all over the world the term CLAD has been introduced, although up to now this term has not clearly been defined. Nevertheless, there is growing awareness that this terminology may be better to identify a chronic, persistent decline in FEV 1 after LTx. As a consequence, this review will focus on 2 different non-BOS phenotypes of CLAD. More specifically, we will focus on neutrophilic reversible allograft dysfunction (NRAD), characterized by an increase in FEV 1 of at least 10% after azithromycin treatment on the one hand, and the recently identified restrictive allograft syndrome (RAS) on the other hand. (9) . Thereafter, more and more studies corroborated the association between excess BAL neutrophilia and the development of chronic rejection and survival after lung transplantation (10) (11) (12) . Moreover, the presence of BAL neutrophils at 3 months and 1 year after transplantation proved to be prognostic for the later development of BOS (13) . Neutrophils were thought to be responsible for the development of obliterative bronchiolitis (OB) via secretion of matrix metalloproteinases (14) , different chemokines and growth factors and oxidative stress (15) , causing damage to the respiratory epithelium, leading to an excess repair process with proliferation of fibroblasts and finally established OB.
Neutrophilic reversible allograft dysfunction

Neomacrolides
The introduction of the neomacrolide antibiotic azithromycin, however, has led to a complete paradigm shift. Gerhardt et al. were the first to use low-dose azithromycin (250 mg three times a week) as an add-on treatment to conventional immunosuppressive therapy in six patients with BOS after LTx. FEV 1 improved in five of these six patients by a mean of 17.1% or 0.50 L over a 4-month period (16). This was later on corroborated by several other groups (17) (18) (19) (20) , all reporting an increase in FEV 1 in at least a subset of patients, clearly illustrating the beneficial effect of azithromycin in established BOS. However, not all studies reported a clear beneficial effect of azithromycin. Shitrit et 5 al. for instance, demonstrated that the overall FEV 1 of 11 LTx patients (BOS 3: n=1; BOS 2: n=6; BOS 1: n=4) had decreased by 1% over 4 months and 2% after 10 months of additional azithromycin treatment. Azithromycin therapy also did not lead to any improvement of BOS status, however, it could at least arrest the progression of the disease (21) . The reason why not all patients responded to azithromycin treatment was not clear at first. In fact, several possible reasons were raised such as a change in calcineurin trough level, the initial BOS stage at the start of azithromycin treatment, colonisation of the airways with Pseudomonads,… (16-19). Later on, however, it became clear that patients who responded to azithromycin, had high BAL IL-8 levels and neutrophilia at the time of diagnosis. Moreover, there was a good correlation between the initial BAL neutrophilia and the FEV 1 response after 3 months of treatment (22) , a finding that was later corroborated by Gottlieb et al. (17) . The observed discrepancy between responders and non-responders disclosed a dichotomy within chronic rejection after lung transplantation. The first phenotype displays a high % of neutrophils in BAL (> 15%), develops rather early after LTx and displays an improvement in FEV 1 of at least 10% after 3 to 6 months of azithromycin treatment. This phenotype was called neutrophilic reversible allograft dysfunction (NRAD) or neutrophilic CLAD (nCLAD). This is in big contrast with the other phenotype, which lacks high BAL neutrophilia (< 15%), develops later and does not respond to azithromycin therapy and was denominated at that moment as fibroproliferative Bronchiolitis Obliterans Syndrome (fBOS) (23, 24) . A randomized double blind placebo-controlled trial recently showed that azithromycin started at discharge from the hospital after LTx could prevent the development of CLAD. The azithromycin group also displayed a better FEV 1 , lower BAL neutrophils and lower systemic C-reactive protein (CRP) levels compared to the placebo group (25) .
At this moment it is still unclear whether a NRAD episode any time during follow-up is a risk factor for the later development of BOS, but it has been shown that NRAD is at least a risk factor for longtime survival after LTx (26) . Azithromycin is not the only macrolide used in post-transplant care, some groups prefer to use clarithromycin, which results in a similar effect in a similar way (responders vs. non-responders) (27) . Caution is needed when using clarithromycin, as it affects the calcineurin trough levels whereas azithromycin does not (28, 29) .
Mechanisms of action of azithromycin
We assume that both the antimicrobial and the anti-inflammatory actions contribute to the beneficial effect of neomacrolide antibiotics. The exact cellular mechanisms are beyond the scope of this review and have already extensively been described previously (30) . Some aspects, however, are important to mention. A human BAL study looking at the expression of 32 different proteins in BOS, NRAD and control patients at the time of diagnosis of CLAD showed that in established NRAD patients MCP-1 , RANTES, IL-1β , IL-8 , TIMP-1, MMP-8 , MMP-9 , HGF, MPO and bile acid concentrations were upregulated, while only PDGF-AA was downregulated compared to control patients (31) . Moreover almost all these proteins were correlated with BAL neutrophilia. None of the proteins were different between azithromycin non-responsive BOS or fBOS and control patients. This is in sharp contrast with previously published data showing that these proteins are indeed involved in the development of BOS (32-34). This further illustrates the importance for adequate phenotyping of BOS. Moreover, one should keep this in mind when looking at previous research as all this work was performed with the understanding of BOS at that time, making interpretation of these results very difficult as we now know that BOS actually represents different phenotypes. An interesting future direction of research is to see whether azithromycin is able to decrease all these proteins to levels comparable to stable patients. It has for instance recently been shown that MMP-9 gelatinase activity is increased in BAL of NRAD patients and following 3-6 months of azithromycin therapy the MMP-9 gelatinase activity significantly decreased. More importantly, these decreased levels were still higher compared to stable patients, which might indicate an ongoing matrix remodeling process, potentially leading to the later development of chronic rejection (35) . An intriguing hypothesis is that IL-17, an important pro-inflammatory cytokine and indirect chemo-attractant of neutrophils, is a key 7 player in NRAD. Evidence derived from either human or mice studies already implicated IL-17 in the pathogenesis of chronic rejection (36) (37) (38) . In vitro data in human airway smooth muscle cells and epithelial cells shows that IL-17 can induce IL-8, a major neutrophil chemo-attractant, but more importantly that azithromycin is able to reduce the IL-17 induced IL-8 production (39, 40, 40) . Further unpublished results show that the number of IL-17 positive lymphocytes in the submucosa increase in NRAD compared to control and azithromycin non-responsive patients. After 3 to 6 months of azithromycin therapy the number of IL-17 positive cells significantly decreased to control levels.
It remains to be added that during azithromycin treatment for NRAD, there may be a recurrence of BAL neutrophilia with or without concurrent FEV 1 decline, the significance and prognosis of which remain to be further elucidated.
Lymphocytic bronchiolitis and NRAD: different entities or not?
Lymphocytic bronchiolitis (LB) is characterized by a lymphocytic infiltration of the airway submucosa and the epithelium and is graded according to the extent of the infiltrate (41) . LB is often accompanied by a decrease in pulmonary function (42) . Glanville et al. showed that LB is a risk factor for the later development of BOS (43) . Regarding treatment of LB, there is conflicting evidence showing that inhaled steroids might bring some relief. One study indeed shows an increase in FEV 1 after treating LB with inhaled steroids (44), while another study could not demonstrate a beneficial effect (42) .
There may actually be a lot of similarities between LB and NRAD. As described above, LB is characterized by a lymphocytic infiltrate in the airway submucosa but a study by Chambers et al. also noticed the presence of a lymphocytic infiltrate in the bronchial/bronchiolar epithelium of established BOS patients. Moreover the number of T-cells in this infiltrate correlated with the BAL neutrophilia (45) . BAL neutrophilia is indeed the most typical characteristic of NRAD patients, but BAL 8 neutrophilia can also be found during episodes of LB. Vos et al. indeed demonstrated that the % BAL neutrophils is significantly higher during LB compared to control patients and patients suffering from acute perivascular rejection (46) . Lastly, when comparing CT scans of LB patients with azithromycin responsive patients, we observe very similar patterns: centrilobular nodules and tree in bud, which resolve after 2-6 months of azithromycin therapy (47). It is our believe that some episodes of LB, especially when accompanied by BAL neutrophilia, may result in a decline in FEV 1 similar to NRAD.
Moreover it seems likely that a negative score for B-grade rejection at diagnosis of NRAD is simply a matter of sampling error as biopsies are very small and can give a skewed image (48) 
Restrictive allograft syndrome
Diagnosis and prognosis
Recently, the Toronto group introduced the term 'restrictive allograft syndrome' (RAS) for patients suffering from a persistent decline in FEV 1 (> 20% compared with the best postoperative values) and an associated restrictive pulmonary function defect, which they defined as a decline in total lung capacity (TLC) >10% compared to baseline (49 Presently, the pathophysiological mechanisms leading to RAS remain elusive. In the Toronto cohort, 12 of 29 patients (41%) had a positive identification of a wide range of micro-organisms in either BAL or sputum at diagnosis, pointing to a possible infectious trigger that might lead to an excessive fibrotic reaction, resulting in a lung with end-stage fibrosis (49) .
Although the terminology may be new, the syndrome seems to have been described previously in autopsy studies. In a report by Martinu et al, studying 12 retransplant lungs, at least 3 patients may now be identified as having RAS with pathology reports showing interstitial fibrosis and radiology showing ground glass opacities, intralobular thickening and areas of fibrosis (50) . Moreover, interstitial changes on transbronchial biopsies are already reported for a long time and seem to occur more frequently later on during follow-up (51). In chronic graft versus host disease with pulmonary manifestation after bone marrow or stem cell transplantation, a similar phenomenon has already been described. This syndrome is denominated as pleuroparenchymal fibro-elastosis and is a very rare complication. Patients manifested with dyspnoea, CT showed pleural thickening, interstitial fibrosis and mosaic patterns, while the pathology demonstrated obliterative bronchiolitis combined with patchy zones of intra-alveolar fibrosis (52, 53) . Unfortunately no detailed pulmonary function tests were performed. In this small case series prognosis was also bad, similar to RAS. The similarities between RAS and pleuroparenchymal fibro-elastosis are hence very striking and might represent a similar pathophysiological mechanism. This is also noted by the Toronto group as they reported the great similarities between the 2 conditions. One of the most remarkable findings of their study is the presence of OB in RAS patients (14/16 patients, 87.5%), which indicates that RAS might in fact be a manifestation of chronic rejection (54) . Pathological analysis of an explant lung at re-transplantation for RAS indeed shows obliteration of the airway ( figure 2A ) with surrounding fibrosis of the alveoli.
Masson's trichrome staining is able to demonstrate accumulation of granulation tissue within the airway lumen and within the parenchyma a dens area of fibrosis is seen ( figure 2B ).
Further research will indicate whether the definition of RAS will stand and whether more different phenotypes of RAS will be defined. In this respect, there may indeed be differences in radiological presentations as some patients do have extensive apical pleural fibrosis, whereas others rather develop interstitial changes throughout the lung, although most apparent in the upper lobes. In this respect, the paper by Pakhale et al (48) 
RAS and Pulmonary function
Woodrow was the first to introduce the term restrictive BOS, based on a decrease of the forced vital capacity (FVC) of at least 20% compared to baseline. This study, however, could not demonstrate a survival disadvantage for the patients suffering from a restrictive pulmonary function, although a trend was seen, probably due to exclusion of patients with persistent infiltrates, who most likely also suffered from a restrictive pulmonary function (57) .
The studies, documenting and describing RAS patients after lung transplantation, used different criteria to diagnose a restrictive pulmonary function. Sato et al defined RAS, along with an FEV 1 decline of at least 20%, as an additional TLC decline of at least 10% compared to baseline. Verleden et al. also incorporated the tiffeneau index to describe restriction and Woodrow, as discussed above, used an FVC decline of at least 20% (25, 45, 51) . Further research will show if there is an easier method to diagnose RAS as TLC measurements are not routinely performed in most centers, although it is advised now to do so. An easier method to diagnose RAS would surely benefit an earlier and a more accurate diagnosis. If this would prove to be ineffective, then more extensive pulmonary function testing will need to be performed more often in the routine transplant patient follow-up.
Two different types of RAS patients are illustrated in figure 3 . One patient shows a very fast evolution towards re-transplantation, while the other patient shows a rather slow evolution.
Risk factors
The only identified risk factor up to now for the later development of RAS is late onset diffuse alveolar damage (DAD occurring later than 3 months after LTx) as 58% of RAS patients suffered from an episode of late onset DAD (58) . The problem, however, is that only approximately 30% of patients with chronic rejection suffer from RAS, making it very difficult to do single-center studies. Multicenter studies are necessary to accurately define risk factors for RAS. Perhaps similar risk factors as compared to BOS (A grade rejection, LB, CMV infection, pseudomonas colonization, gastrooesophageal reflux, …) will prove to be important for the later development of RAS (59) . Some new risk factors may arise such a genetic predisposition towards the development of RAS. Interesting in that perspective is the fact that a MUC5B polymorphism has been demonstrated to be an important genetic predictor for Idiopathic Pulmonary Fibrosis (IPF) (60) , which may in some way resemble RAS development. This has hitherto not been investigated in the development of RAS.
Since serum KL-6 levels, a marker of fibroblast proliferation, are increased in RAS patients compared to BOS patients (61) , this may strengthen this hypothesis as KL-6 is also a marker for IPF or CF, diseases characterized by interstitial fibrosis (62, 63) . The patient cohort was, however, rather small, and future studies might be able to corroborate the potential role of this intriguing marker.
In the Toronto experience, neither age (donor/receptor), type of transplantation, original diagnosis for LTx, CMV (mis-)match and acute rejection proved to be risk factors for the later development of RAS (49).
Treatment
As the concept of RAS is rather new, no valid treatment has been proposed yet. At this moment the influence of conventional BOS treatment options like total lymphoid irradiation (64), photophoresis (65) and montelukast (66) is not clear. In our experience azithromycin does not bring relief to these patients. Perhaps we should look outside the field of lung transplantation and extend our horizon to IPF, a disease with much similarities to RAS as the etiology of the disease is unknown, radiology looks similar (consolidation zones, reticular patterns) and histology shows end-stage fibrosis. A beneficial effect of pirfenidone has been shown to slow down the decline in FVC in patients with established IPF (67) . Pirfenidone suppresses TNF-α production and influences the production of TGF-β (68).
Moreover, in vitro studies showed that pirfenidone was able to slow down proliferation of human 14 lung fibroblast cells (69) . Even within the lung transplant setting, there is some evidence that pirfenidone might bring relief, although this evidence is mostly based on animal studies. Both in a murine heterotopic tracheal transplantation model (70, 71) and a rat orthotopic lung transplantation model, pirfenidone has been shown to reduce fibrosis (72) . At this moment, however, the only treatment that can bring relief in well-selected patients is re-transplantation. Another drug that might be of help is the CD52 antagonist alemtuzumab (Campath-1H). CD52 is a protein expressed on B-cells, lymphocytes, dendritic cells and monocytes and was first used in lung transplantation to treat recurrent acute rejection episodes, which were untreatable with conventional treatment protocols 
Conclusion
Phenotyping CLAD has very important implications towards clinical practice. NRAD patients are most easily to diagnose using BAL fluid and these patients will recover following azithromycin treatment (as per definition) and have a very good prognosis. RAS patients are diagnosed using TLC and CATscans and have a much worse prognosis. Unless other treatments become available to treat RAS, this implicates that possible re-transplantation should be considered quickly after diagnosis as prognosis is bad. Moreover phenotyping CLAD also has important scientific implications as most previous studies used a pool of patients suffering from BOS/CLAD whereas it is now presumed that each 
